Interleukin 13-mediated colitis in the absence of IL-4Rα signalling

Jennifer C Hoving^{1

2}, Antony J Cutler^{1

2

3}, Mosiuoa Leeto^{1

2}, William G C Horsnell^{1

2}, Benjamin G Dewals^{1

2

4}, Natalie E Nieuwenhuizen^{1

2

5}, Frank Brombacher^{1

2}

Affiliations

¹ International Centre for Genetic Engineering and Biotechnology (ICGEB), Cape Town Component, Cape Town, South Africa.
² Division of Immunology, Institute of Infectious Diseases and Molecular Medicine (IDM), Faculty of Health Sciences, University of Cape Town and South African Medical Research Council (SAMRC), Cape Town, South Africa.
³ JDRF/Wellcome Trust Diabetes and Inflammation Laboratory, Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, UK.
⁴ Fundamental and Applied Research in Animals and Health, Faculty of Veterinary Medicine, University of Liege, Belgium.
⁵ Department of Immunology, Max Planck Institute for Infection Biology, Berlin, Germany.

PMID: 28246312
DOI: 10.1136/gutjnl-2016-313208

Comment

Interleukin 13-mediated colitis in the absence of IL-4Rα signalling

Jennifer C Hoving et al. Gut. 2017 Nov.

. 2017 Nov;66(11):2037-2039.

doi: 10.1136/gutjnl-2016-313208. Epub 2017 Feb 28.

Authors

Jennifer C Hoving^{1

2}, Antony J Cutler^{1

2

3}, Mosiuoa Leeto^{1

2}, William G C Horsnell^{1

2}, Benjamin G Dewals^{1

2

4}, Natalie E Nieuwenhuizen^{1

2

5}, Frank Brombacher^{1

2}

Affiliations

¹ International Centre for Genetic Engineering and Biotechnology (ICGEB), Cape Town Component, Cape Town, South Africa.
² Division of Immunology, Institute of Infectious Diseases and Molecular Medicine (IDM), Faculty of Health Sciences, University of Cape Town and South African Medical Research Council (SAMRC), Cape Town, South Africa.
³ JDRF/Wellcome Trust Diabetes and Inflammation Laboratory, Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, UK.
⁴ Fundamental and Applied Research in Animals and Health, Faculty of Veterinary Medicine, University of Liege, Belgium.
⁵ Department of Immunology, Max Planck Institute for Infection Biology, Berlin, Germany.

PMID: 28246312
DOI: 10.1136/gutjnl-2016-313208

No abstract available

Keywords: CYTOKINES; IMMUNE RESPONSE; INTERLEUKINS; ULCERATIVE COLITIS.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Comment on

Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study.
Danese S, Rudziński J, Brandt W, Dupas JL, Peyrin-Biroulet L, Bouhnik Y, Kleczkowski D, Uebel P, Lukas M, Knutsson M, Erlandsson F, Hansen MB, Keshav S. Danese S, et al. Gut. 2015 Feb;64(2):243-9. doi: 10.1136/gutjnl-2014-308004. Epub 2014 Oct 10. Gut. 2015. PMID: 25304132 Clinical Trial.
Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study.
Reinisch W, Panés J, Khurana S, Toth G, Hua F, Comer GM, Hinz M, Page K, O'Toole M, Moorehead TM, Zhu H, Sun Y, Cataldi F. Reinisch W, et al. Gut. 2015 Jun;64(6):894-900. doi: 10.1136/gutjnl-2014-308337. Epub 2015 Jan 7. Gut. 2015. PMID: 25567115 Clinical Trial.

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- HighWire
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Interleukin 13-mediated colitis in the absence of IL-4Rα signalling

Affiliations

Interleukin 13-mediated colitis in the absence of IL-4Rα signalling

Authors

Affiliations

Conflict of interest statement

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources